Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG002C0106 in Primary IgA Nephropathy
NCT07305974Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2029
- Countries
- 1
- Sponsor
- Rigerna Therapeutics
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Drugs
- RG002C0106
- Conditions
- IgA nephropathy (IgAN)
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing RG002C0106 with placebo (2 arms). Primary endpoints: 24-hour Urine Protein-to-Creatinine Ratio at 24 weeks and Adverse Events and Serious Adverse Events at 169 days. Started Sep 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Experimental: RG002C0106
Subcutaneous injection of RG002C0106
Placebo Comparator: placebo
Subcutaneous injection of placebo (normal saline)
03
Who it enrols
Adults aged 18-65 with primary IgA nephropathy, 24-hour urinary protein ≥ 0.75 g/24 h, and eGFR ≥ 30 mL/min/1.73 m².
04
Endpoints
Primary
24-hour Urine Protein-to-Creatinine Ratio
Adverse Events and Serious Adverse Events
Beyond the preview
Go deeper on NCT07305974.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305974.